XML 44 R34.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Stock-Based Compensation (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract] |
Schedule of Stock Option Activity | A summary of the stock option activity under the Company’s equity plans and inducement awards for the nine months ended September 30, 2022 is as follows:
(number of shares in millions) | Number of Shares |  | Weighted Average Exercise Price
Options outstanding at December 31, 2021 | 1.4 |  |  | $ | 20.36 |
Less: |  |  |
Options exercised | — |  |  | $ | 26.22 |
Options canceled or expired | (0.6) |  |  | $ | 26.85 |
Options outstanding at September 30, 2022 | 0.8 |  |  | $ | 15.62 |
Options exercisable at September 30, 2022 | 0.5 |  |  | $ | 16.99 |
Schedule of Restricted Stock Unit Activity | A summary of the RSU awards activity under the Company’s equity plans and inducement awards, including PSU awards, for the nine months ended September 30, 2022 is as follows:
(number of shares in millions) | Number of Shares |  | Weighted Average Grant Date Fair Value
RSUs outstanding at December 31, 2021 | 3.1 |  |  | $ | 24.96 |
RSUs granted | 1.9 |  |  | $ | 26.09 |
Less: |  |  |
RSUs vested | (1.0) |  |  | $ | 27.27 |
RSUs canceled | (0.3) |  |  | $ | 26.57 |
RSUs outstanding at September 30, 2022 | 3.7 |  |  | $ | 24.75 |
Schedule of Stock-Based Compensation Expense | Stock-based compensation expense recognized and included in the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) was allocated as follows:
| Three months ended September 30, |  | Nine months ended September 30,
(in millions) | 2022 |  |  | 2021 |  | 2022 |  |  | 2021
Cost of molecular diagnostic testing | $ | 0.5 |  |  |  | $ | 0.4 |  |  | $ | 1.3 |  |  |  | $ | 1.1 |
Cost of pharmaceutical and clinical services | — |  |  |  | — |  |  | — |  |  |  | 0.1 |
Research and development expense | 1.0 |  |  |  | 0.8 |  |  | 4.4 |  |  |  | 3.3 |
Selling, general, and administrative expense | 7.9 |  |  |  | 8.8 |  |  | 24.2 |  |  |  | 23.4 |
Total stock-based compensation expense | $ | 9.4 |  |  |  | $ | 10.0 |  |  | $ | 29.9 |  |  |  | $ | 27.9 |

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 + Details
Name: | us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration